CAS 4291-63-8|Cladribine

Introduction：Basic information about CAS 4291-63-8|Cladribine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Cladribine BiologicalActivity
3. Chemical & Physical Properties
4. Toxicological Information
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
MUTATION DATA
5. Safety Information
6. Articles78
7. Synonyms

Common Name	Cladribine
CAS Number	4291-63-8	Molecular Weight	285.687
Density	2.0±0.1 g/cm3	Boiling Point	547.6±60.0 °C at 760 mmHg
Molecular Formula	C₁₀H₁₂ClN₅O₃	Melting Point	181-185 °C(lit.)
MSDS	ChineseUSA	Flash Point	285.0±32.9 °C
Symbol	GHS06	Signal Word	Danger

Names

Name	cladribine
Synonym	More Synonyms

Cladribine BiologicalActivity

Description	Cladribine is an adenosine deaminase inhibitor used to treat hairy cell leukemia and multiple sclerosis. Target: Adenosine DeaminaseCladribine possesses concentration-dependent apoptosis-inducing potential in the HSB2 cells. Cladribine inhibits growth of primary mast cell (MC) and the MC line HMC-1 in a dose-dependent manner, with lower IC50 values recorded in HMC-1.2 cells harboring KIT D816V compared to HMC-1.1 cells lacking KIT D816V. Cladribine (0.7-3.5 mM) and/or diltiazem (2.4 mM), is injected intraperitoneally into adult zebrafish and red blood cell (RBC) lysates are assayed by HPLC for levels of purine nucleotides (e.g. ATP), potential biomarkers of cardiovascular health. Diltiazem increased RBC ATP concentrations, which are inhibited by co-injection of cladribine.
Related Catalog	Signaling Pathways >>Metabolic Enzyme/Protease >>Adenosine DeaminaseResearch Areas >>Cardiovascular Disease
References	[1]. Guchelaar, H.J., et al., Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Cancer Chemother Pharmacol, 1998. 42(1): p. 77-83. [2]. Bohm, A., et al., In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol, 2010. 38(9): p. 744-55. [3]. Klein, L.C., P.K. Yeung, and J.N. Berman, Cladribine inhibits a diltiazem-induced increase in red blood cell purine nucleotide concentrations in a zebrafish model. Biomarkers, 2009. 14(8): p. 554-9.

Description

Cladribine is an adenosine deaminase inhibitor used to treat hairy cell leukemia and multiple sclerosis. Target: Adenosine DeaminaseCladribine possesses concentration-dependent apoptosis-inducing potential in the HSB2 cells. Cladribine inhibits growth of primary mast cell (MC) and the MC line HMC-1 in a dose-dependent manner, with lower IC50 values recorded in HMC-1.2 cells harboring KIT D816V compared to HMC-1.1 cells lacking KIT D816V. Cladribine (0.7-3.5 mM) and/or diltiazem (2.4 mM), is injected intraperitoneally into adult zebrafish and red blood cell (RBC) lysates are assayed by HPLC for levels of purine nucleotides (e.g. ATP), potential biomarkers of cardiovascular health. Diltiazem increased RBC ATP concentrations, which are inhibited by co-injection of cladribine.

Related Catalog

Signaling Pathways >>Metabolic Enzyme/Protease >>Adenosine DeaminaseResearch Areas >>Cardiovascular Disease

References

[1]. Guchelaar, H.J., et al., Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Cancer Chemother Pharmacol, 1998. 42(1): p. 77-83.

[2]. Bohm, A., et al., In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol, 2010. 38(9): p. 744-55.

[3]. Klein, L.C., P.K. Yeung, and J.N. Berman, Cladribine inhibits a diltiazem-induced increase in red blood cell purine nucleotide concentrations in a zebrafish model. Biomarkers, 2009. 14(8): p. 554-9.

Chemical & Physical Properties

Density	2.0±0.1 g/cm3
Boiling Point	547.6±60.0 °C at 760 mmHg
Melting Point	181-185 °C(lit.)
Molecular Formula	C₁₀H₁₂ClN₅O₃
Molecular Weight	285.687
Flash Point	285.0±32.9 °C
Exact Mass	285.062866
PSA	119.31000
LogP	0.02
Vapour Pressure	0.0±1.5 mmHg at 25°C
Index of Refraction	1.871
Storage condition	2-8°C
Stability	Store in Freezer

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: AU7357560

CHEMICAL NAME :: Adenosine, 2-chloro-2'-deoxy-

CAS REGISTRY NUMBER :: 4291-63-8

LAST UPDATED :: 199807

DATA ITEMS CITED :: 5

MOLECULAR FORMULA :: C10-H12-Cl-N5-O3

MOLECULAR WEIGHT :: 285.72

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 700 ug/kg/7D-C

TOXIC EFFECTS :: Skin and Appendages - dermatitis, other (after systemic exposure)

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 150 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 100 mg/kg/5D-I

TOXIC EFFECTS :: Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Primate - monkey

DOSE/DURATION :: 7 mg/kg/7D-C

TOXIC EFFECTS :: Gastrointestinal - hypermotility, diarrhea Blood - granulocytopenia

MUTATION DATA

TYPE OF TEST :: DNA inhibition

TEST SYSTEM :: Human Lymphocyte

DOSE/DURATION :: 16 nmol/L

REFERENCE :: CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 46,2362,1986

Safety Information

Symbol	GHS06
Signal Word	Danger
Hazard Statements	H301 + H311 + H331-H315-H319-H335
Precautionary Statements	Missing Phrase - N15.00950417-P261-P280-P302 + P352 + P312-P304 + P340 + P312-P403 + P233
Personal Protective Equipment	Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
Hazard Codes	T:Toxic
Risk Phrases	R23/24/25;R36/37/38
Safety Phrases	S26-S37/39-S45-S36-S22
RIDADR	NONH for all modes of transport
WGK Germany	3
RTECS	AU7357560

Articles78

The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.

Eur. J. Cancer 51 , 2008-21, (2015)

MLL-rearranged acute lymphoblastic leukaemia (ALL) in infants is the most difficult-to-treat type of childhood ALL, displaying a chemotherapy-resistant phenotype, and unique histone modifications, gen...

Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study.

Cancer Chemother. Pharmacol. 75 , 897-906, (2015)

Clofarabine, a deoxyadenosine analog, was an active anticancer drug in our in vitro high-throughput screening against mouse ependymoma neurospheres. To characterize the clofarabine disposition in mice...

Cladribine in the treatment of acute myeloid leukemia.

Leuk. Res. 38(4) , 425-7, (2014)

Synonyms

Litak

CDA

2-Chloro-2'-deoxyadenosine

2-Chloro-9-(2-deoxy-β-D-arabinofuranosyl)adenine

2-Chloro-2'-deoxy-adenosine

CldAdo

EINECS 224-427-9

MFCD00153939

(2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxyméthyl)tétrahydrofuran-3-ol

2-chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purine

Cladrivine

2CDA

2-Chloro-6-amino-9-(2-deoxy-b-D-erythro-pentofuranosyl)purine

Cladaribine

(2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol

2-Chlorodeoxyadenosine

leustatin

(2R,3S,5R)-5-(6-Amino-2-chlor-9H-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol

2-Chloro-2'-deoxy-b-adenosine

2-Chloro-2'-deoxy-β-adenosine

2-CL-DADO

Cladribine

Movectro

Leustati

adenosine, 2-chloro-2'-deoxy-

Recommended......